Signals

NVD · CVE-2026-7726 · 6.5 · The Layouts for WPBakery plugin for WordPress is vulnerable to unauthorized actions due to a missing capability check on the `Layouts_WPB_Remote::template_sync(NVD · CVE-2026-7693 · 7.2 · The Backup Migration plugin for WordPress is vulnerable to OS Command Injection in all versions up to, and including, 2.1.5.1 due to insufficient sanitization oNVD · CVE-2026-7520 · 8.1 · The MailChimp Forms by MailMunch plugin for WordPress is vulnerable to unauthorized modification of data due to a missing capability check on the `sign_in()` anNVD · CVE-2026-7444 · 8.1 · The Search Analytics for WP plugin for WordPress is vulnerable to Cross-Site Request Forgery in all versions up to, and including, 1.4.16. This is due to missinCISA KEV · CVE-2026-18556 · 7.4 · N-able N-central Authentication Bypass Using an Alternate Path or Channel Vulnerability · Added 2026-08-04 · Due 2026-08-07CISA KEV · CVE-2026-34486 · 7.5 · Apache Tomcat Missing Encryption of Sensitive Data Vulnerability · Added 2026-08-04 · Due 2026-08-07NVD · CVE-2026-7726 · 6.5 · The Layouts for WPBakery plugin for WordPress is vulnerable to unauthorized actions due to a missing capability check on the `Layouts_WPB_Remote::template_sync(NVD · CVE-2026-7693 · 7.2 · The Backup Migration plugin for WordPress is vulnerable to OS Command Injection in all versions up to, and including, 2.1.5.1 due to insufficient sanitization oNVD · CVE-2026-7520 · 8.1 · The MailChimp Forms by MailMunch plugin for WordPress is vulnerable to unauthorized modification of data due to a missing capability check on the `sign_in()` anNVD · CVE-2026-7444 · 8.1 · The Search Analytics for WP plugin for WordPress is vulnerable to Cross-Site Request Forgery in all versions up to, and including, 1.4.16. This is due to missinCISA KEV · CVE-2026-18556 · 7.4 · N-able N-central Authentication Bypass Using an Alternate Path or Channel Vulnerability · Added 2026-08-04 · Due 2026-08-07CISA KEV · CVE-2026-34486 · 7.5 · Apache Tomcat Missing Encryption of Sensitive Data Vulnerability · Added 2026-08-04 · Due 2026-08-07

ClaimedMedium

FUJIFILM

Technology · JP · sarcoma

All intelligence content is fictional, redacted and defensive. No real credentials, stolen data, exploit instructions, malware links, payment information or private personal data is published. Derived from public data-leak-site monitoring. Presented for defensive awareness only; unverified attacker claims.

Public preview

Public summary and status visible. Pro+ adds detailed defensive context and analysis.

Plans →

Public Summary

Actions

View pricing →

Full Summary

Fujifilm has actively promoted the research and development of liposome formulations by harnessing its advanced nano-dispersion technology, analysis technology, and process technology cultivated and evolved through its wide range of product development. In 2017, the company began a U.S. Phase I clinical trial of FF-10832, a liposome-based agent that encapsulates the approved anti-cancer agent gemcitabine *** . In the preclinical mice studies on FF-10850 and FF-10832 *4 Fujifilm has observed the extension of the survival period as a result of immune checkpoint inhibitor *5 combination therapy. In addition, Fujifilm has been promoting the application of liposome for use with next-generation drugs such as nucleic acid drugs and gene therapy drugs. Looking towards future growth, in order to ensure a stable supply of high-quality liposome formulations, Fujifilm is developing a manufacturing facility for producing investigational and commercial drugs through its subsidiary, FUJIFILM Toyama.Geo: Singapore - Leak size: NO DATA 1 pdf - Contains: NO DATA 1 pdf

Status

Claimed

Impact

Medium

Sector

Technology

Country